Φορτώνει......

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation b...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:	Blood
Κύριοι συγγραφείς:	Amatangelo, Michael D., Quek, Lynn, Shih, Alan, Stein, Eytan M., Roshal, Mikhail, David, Muriel D., Marteyn, Benoit, Farnoud, Noushin Rahnamay, de Botton, Stephane, Bernard, Olivier A., Wu, Bin, Yen, Katharine E., Tallman, Martin S., Papaemmanuil, Elli, Penard-Lacronique, Virginie, Thakurta, Anjan, Vyas, Paresh, Levine, Ross L.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	American Society of Hematology 2017
Θέματα:	Clinical Trials and Observations
Διαθέσιμο Online:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5553578/ https://ncbi.nlm.nih.gov/pubmed/28588019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779447
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Παρόμοια τεκμήρια